DUSAN PEKOVIC: Open Payments
NPI 1568532687 · NEW YORK CITY, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,962 in 89 payments from 13 companies in 2025. Trend: 2023 $5,910 · 2024 $3,982 · 2025 $2,962
Food & beverage: $2,962
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 14 | $428 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $423 |
| E.R. Squibb & Sons, L.L.C. | 7 | $376 |
| ABBVIE INC. | 15 | $357 |
| Lundbeck LLC | 12 | $319 |
| Otsuka America Pharmaceutical, Inc. | 10 | $258 |
| Alkermes, Inc. | 8 | $256 |
| Axsome Therapeutics, Inc. | 3 | $172 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $172 |
| Janssen Pharmaceuticals, Inc | 3 | $92 |
Products named: FANAPT, CAPLYTA, COBENFY, VRAYLAR, REXULTI, ABILIFY ASIMTUFII, LYBALVI, Auvelity.
Industry payments across NY — which companies pay providers there.
